Sanofi ends development of CEACAM5-targeting ADC tusamitamab ravtansine after it fails a phase 3 trial in non-small cell lung cancer (NSCLC) ...

IBI3020: CEACAM5 dual-payload ADC as globally the first to enter clinical phase IBI363: Next-Gen IO Redefining Cancer Immunotherapy ...

IBI3001 (EGFR/B7H3 ADC): dual-targeted ADC with broad potential in solid tumors IBI3020 (CEACAM5 dual payload ADC): designed for high efficacy and low toxicity in treatment-resistant tumors ...

SAN FRANCISCO and SUZHOU, China, June 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and ...

Germany's Merck KGaA has said it needs to double the productivity of its R&D operations, with the aim of launching a new product every 18 months on average, to boost its pharma business. The ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, ...

Precemtabart tocentecan is currently being evaluated across tumor types with CEACAM5 expression and a high unmet need, including metastatic colorectal cancer (mCRC), gastric cancer (GC), non-small ...